Business Context and Reporting Period
This Form 8-K filing by IRADIMED CORP (IRMD) was submitted on August 23, 2019. The report discloses a material corporate event regarding the retirement of a senior executive and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and separation terms.
Material Changes
The primary material change reported is the execution of a First Amended and Restated Separation Agreement with John McCreery, the Company's Chief Operating Officer (COO), effective August 23, 2019. Key terms include:
- Transition Period: Mr. McCreery will continue serving as COO until his retirement date of January 6, 2020.
- Bonus Eligibility: He remains eligible to receive the 2019 annual bonus.
- Paid Time Off: A one-time addition of 40 hours to his total paid time-off balance.
- Equity Acceleration: Accelerated vesting of the third tranche of his initial restricted stock unit (RSU) award, totaling 15,625 shares of common stock, to be vested on the Retirement Date.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of general business risks. The only contingency noted is the transition of duties following Mr. McCreery's retirement in early 2020.
Investor Verification Checklist
- Verify the full terms of the First Amended and Restated Separation Agreement filed as Exhibit 10.1.
- Confirm the impact of the accelerated vesting of 15,625 shares on the company's share count and dilution.
- Monitor the appointment of a successor to the Chief Operating Officer role prior to the January 6, 2020 retirement date.
- Review subsequent filings for the actual payout of the 2019 annual bonus and any related accounting charges.